MedPAC On Steroids: The Implications of a New Medicare Advisory Council
This article was originally published in RPM Report
Executive Summary
The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.
You may also be interested in...
IPAB Repeal Gets a Big Boost—From a Footnote
CBO’s latest assumptions about Medicare spending over time have an important implication: the trigger for action by the newly created Independent Payment Advisory Board is no longer predicted to occur. That makes industry’s call to repeal the board suddenly more possible--though the Administration won't let IPAB go without a fight.
Health Care Reform and Business Development: 10 Reasons it Matters
The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.
Health Care Reform and Business Development: 10 Reasons It Matters
The drama of the US health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.